Dr. Keedy on Regorafenib for the Treatment of GIST

Vicki Keedy, MD
Published: Tuesday, Nov 12, 2013

Vicki Keedy, MD, Assistant Professor of Medicine, Clinical Director, Sarcoma Program, Vanderbilt-Ingram Cancer Center, discusses the use of regorafenib for the treatment of patients with GIST.

Once patients progressed through imatinib and sunitinib, they had no FDA-approved options to treat their GIST. Many of these patients were treated off-label and by community doctors, rather than seek treatment on a clinical trial at an academic center.

Regorafenib provides an effective third-line drug, but Keedy says patients still are not coming onto clinical trials.

Vicki Keedy, MD, Assistant Professor of Medicine, Clinical Director, Sarcoma Program, Vanderbilt-Ingram Cancer Center, discusses the use of regorafenib for the treatment of patients with GIST.

Once patients progressed through imatinib and sunitinib, they had no FDA-approved options to treat their GIST. Many of these patients were treated off-label and by community doctors, rather than seek treatment on a clinical trial at an academic center.

Regorafenib provides an effective third-line drug, but Keedy says patients still are not coming onto clinical trials.


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Moving Forward From the Status Quo for the Treatment of Soft Tissue Sarcoma: Key Questions & New Answers to Optimize OutcomesAug 16, 20181.5
Clinical Interchange™: Moving Forward From the Status Quo for the Treatment of Soft Tissue Sarcoma: Key Questions and New Answers to Optimize OutcomesOct 31, 20182.0
Publication Bottom Border
Border Publication
x